Recommended
More Related Content
What's hot
What's hot (20)
Similar to Fanconi
Similar to Fanconi (20)
More from Jan-Gert Nel
More from Jan-Gert Nel (10)
Recently uploaded
Recently uploaded (20)
Fanconi
- 1. Fanconi anaemia JG Nel Department of Haematology and Cell Biology UFS June 2010
- 2. History ā¢ Most frequently reported IBFS ā¢ First described in 1927 by a Swiss Paediatrician ā¢ Noted a family with three brothers who had: ā« āperniziosiforme anaemiaā ā« Several physical abnormalities ļ Microcephaly ļ Skin hyperpigmentation
- 3. History ā¢ Decades of research into FA led Fanconi to believe that a mutation of a single gene could not account for the clinical heterogeneity observed amongst FA patients
- 4. History ā¢ In 1960s observed by several groups that cultured cells from patients with FA had an increased number of chromosomal breaks, the number of breaks were specifically increased with the addition of specific agents ā¢ Cell cycle gap in gap2/mitosis also occurred at lower concentrations of clastogens than in normal cells
- 5. In this presentation: Fanconi anaemia: ā¢ Clinical features ā¢ Molecular and cell biology ā¢ Principles of management ā¢ Morbidity and mortality
- 6. Clinical features ā¢ Usually inherited as an autosomal recessive trait ā¢ Can be X-linked recessive ā¢ FA patients display progressive bone marrow failure and an increased predisposition to malignancy
- 7. Physical findings reported in the literature ā¢ 60% of reported patients had at least one feature ā¢ Microsomia 40% of cases
- 8. Physical findings reported in the literature Dermatological 40% ā¢ CafĆ© au lait ā¢ Generalized hyper- pigmentation ā¢ Hypo-pigmented areas
- 9. Physical findings reported in the literature Upper limbs 35% ā¢ Thumbs: (35%) ā« Absent /hypoplastic, bifid, duplicated, rudimentary , attached by a thread, triphalangeal, long, low set ā¢ Radii: (7%) ā« Absent or hypoplastic, absent or weak pulse ā¢ Hands: (5%) ā« Flat thenar eminence, absent first metacarpal, clinodactyly, polydactyly ā¢ Ulnae: (1%) ā« Dysplastic, short
- 10. Physical findings reported in the literature Skeletal ā¢ Head: (20%) ā« Microcephaly, hydrocephaly ā¢ Face: (2%) ā« Triangular, birdlike, dysmorphic, micrognathia, mid face hypoplasia ā¢ Neck: (1%) ā« Spengel, Klippel-Feil, short, low hairline, web ā¢ Spine: (2%) ā« Spina bifida, scoliosis, hemivertebrae, abnormal ribs, coccygeal hypoplasia
- 11. Physical findings reported in the literature ā¢ Eyes: (20%) ā« Small, strabismus, epicanthal folds, hypotelorism, hypertelorism, cataracts, astignatism ā¢ Renal: (20%) ā« Horseshoe, ectopic or pelvic, abnormal, hypoplastic or dysplastic, absent, hydronephrosis, hydro ureter ā¢ Gonads: ā« Males: (25%) ļ Hypogenitalia, undescended testes, hypospadias, micropenis, absent testes ā« Females: (1%) ļ Hypogenitalia, bicornuate uterus, malposition, small ovaries
- 12. Physical findings reported in the literature Gastro-intestinal: (5%) ā« Atresia, imperforate anus, TOF, annular pancreas, malrotation Cardiopulmonary: (6%) ā« Cong heart dis, PDA, ASD, VSD, coarctation, situs inversus, truncus arteriosus Central nervous system: (3%) ā« Small pituitary stalk, pitituiary stalk int synd, absent corpus callosum, cerebral hypoplasia, hydrocephalus
- 13. Clinical features ā¢ Affected individuals may have one or more somatic abnormalities ā« Dermatological ā« Skeletal ā« Genitourinary ā« Gastro intestinal ā« Cardiac ā« Neurological ā¢ 1/3 of patients have no overt somatic abnormalities
- 14. Clinical features ā¢ Patients with a high congenital abnormality score(CABS) are at greater risk for developing aplastic anaemia, whilst patients with lower CABS are at greater risk of developing solid tumours or leukaemia as young adults
- 15. Getting to the heart of the matterā¦
- 16. Fanconi anaemia: Molecular and cell biology ā¢ Wide range of clinical findings can be explained by the fact that FA is a chromosomal instability disorder ā« Cells from FA patients accumulate damage at an increased rate ā« Unrepaired DNA damage can: ļ Activate pro-apoptotic pathways āleading to depletion of haematopoietic stem cellsā¦ ļ Can lead to mutations and translocations that cause inactivation of cell cycle barriers leading to tumour genesis
- 17. Fanconi anaemia: Molecular and cell biology ā¢ Abnormal cell cycle kinetics ā« Prolonged G2 phase ā« Increased apoptosis ā« Accelerated telomere shortening ā¢ Most striking cellular hallmark of FA ā« Hypersensitivity to a class of DNA damaging agents that create DNA interstrand crosslinks(ICL)
- 18. Interstrand crosslinks ā¢ Covalent links that prevent DNA from unwinding ā« Blocks transcription and translation ā¢ Difficult to repair, a single DNA repair pathway inadequate ā¢ Affects both strands of the helix ā¢ Main function of the FA pathway is to coordinate several distinct repair activities
- 19. Interstrand crosslinks ā¢ Induced by: ā« Mitomycin C ā« DEB ā« ?products of the endogenous metabolism of certain cells ļ ?products of lipid metanolism in the liver
- 20. The classic Fanconi Anaemia genes ā¢ Considerable genetic heterogeneity ā« 13 subtypes/complementation groups identified ā« Most inherited in an autosomal recessive fashion ā« FANCB -X linked recessive FANCA FANCB FANCC FANCD1 FANCD2 FANCE FANCF FANCG FANCI FANCJ/BRIP1 FANCL FANCM FANCN/PALB2
- 21. The core complex ā¢ Majority of FA proteins form a complex with ubiquitin ligase activity ā¢ Majority of FA patients harbour mutations in the genes that encode the core complex
- 22. FANCM and FAAP24: targeting the core complex to DNA ā¢ Belong to the endonuclease family ā¢ Normally operate as heterodimers ā¢ Nuclease domains ā« Required for dimerization ā« DNA binding ā« No nuclease activity ā¢ Recognize stalled replication forks ā¢ Recruit the core complex to ubiquinate itās targets
- 23. Ubiquination ā¢ Ubiquitin ā« Smal highly conserved regulatory protein ā« Ubiquitously expressed ā¢ Ubiquination ā« Post ātranslational modification of a protein by the covalent attachment of one or more ubiquitin monomers ā¢ Functions: ā« Labeling proteins for proteasomal degradation ā« Also modulates ļ Stability ļ Function ļ Intracellular localization
- 24. FANCD2 and FANCI: substrates for ubiquination ā¢ Dynamic complex that moves in and out of chromatin ā¢ Monoubiquination considered an essential step in FAP activation ā¢ Ubiquination of FANCD2-I complexes leads to localization on chromatin foci ā¢ DNA repair structures ā« Interacts with DNA repair proteins ļ BRCA2,BRCA1,RAD51
- 25. FANCD2 and FANCI: substrates for ubiquination ā« BRCA2 ļ important in DNA repair by homologous recombination ļ Cells lacking BRCA2- inaccurately repair damaged DNA ā« FANCJ (BRIP1)-āpartner of BRCA1ā ā« FANCN(PALB2)-āpartner of BRCA2ā
- 26. The repair of interstrand crosslinks ā¢ DNA replication blocked at crosslink ā¢ DSB generated by endonucleases ā« Uncouples one sister chromatid from the other ā« Crosslinked base can then be unhooked
- 27. The repair of interstrand crosslinks ā« Remaining structure bypassed by specialized polymerases that are able to replicate through DNA lesions ā« Bypassed unhooked crosslink can be repaired by hydrolysis or nucleotide replacement allowing re-establishment of the replication fork ļ Likely by HR machinery mediated invasion of the repaired chromatid by the sister
- 28. ICL repair pathways controlled by FAP ā¢ Nucleotide excision repair (NER) ā¢ Homologous recombination (HR) ā¢ Translesion synthesis (TLR)
- 29. Nucleotide excision repair ā¢ NER endonucleases perform the initial incisions that unhook the crosslink ā¢ Cleavage achieved in a highly coordinated manner ā¢ Two structure-specific heterodimeric endonucleases ā« Erccl-XPF ā« Mus81-Eme1 ā¢ Erccl-XPF cleavage step required for efficient recruitment of FANCD2 to the site of ICL repair
- 30. Homologous recombination ā¢ Repair initiated by resection of double strand break ā« Leaving 3ā single stranded overhangs ā¢ Central action of HR is homology search and strand invasion by ssDNA-Rad51 filament ā¢ Strand invasion into a homologous sequence is followed DNA synthesis at the invading end
- 31. Homologous recombination ā¢ After strand invasion and synthesis, the second DSB end can be captured to form an intermediate ā¢ After gap repair, DNA synthesis and ligation the structure is resolved
- 32. Translesion synthesis ā¢ DNA damage tolerance process ā¢ Allows the DNA replication machinery to replicate past lesions ā¢ Involves switching out regular DNA polymerases for specialized translesion polymerases
- 33. Translesion synthesis ā¢ Translesion polymerases ā« Larger active sites āthat can insert bases opposite damaged nucleotides ā« Often have low fidelity (high propensity to insert wrong bases) relative to regular polymerases ā« Many are extremely efficient at inserting the right bases oppsite specific types of damage
- 34. Translesion synthesis ā¢ Risking the introduction of point mutations during translesion synthesis may be preferable to more drastic mechanisms of DNA repair
- 35. Fanconi anaemia: The FA/BRCA pathway ā¢ FA/BCRA pathway activated by ATR and RAD3 related protein ā« ATR directly regulates FA pathway ļ Monoubiquination of FANCD2 ļ Phosphorilates FANCD2 at several sites
- 36. Management: HSCT ā¢ Only cure for haematological complications is HSCT ā¢ Timing of HSCT remains a challenge ā« Outcomes are best prior to the development of complications ļ Infections fromCSN ļ High transfusion burden ļ Development of MDS/AML ā« Many patients do not progress to severe marrow failure or acute leukaemia
- 37. Management: HSCT ā¢ Patients with FA are VERY sensitive to genotoxic agents ā« Cyclophosphamide ā« Busulphan ā« Ionizing radiation ā¢ Also sensitive to the damaging effects of graft vs host disease
- 38. Management: HSCT ā¢ Reduced doses for transplant preparative regimens ā¢ Nongenotoxic regimens to prevent graft-versus-host disease ā¢ The use of reduced-intensity conditioning has resulted in greatly improved transplant outcomes ā¢ Fludarabine ā« Highly immunosuppressive and myelosuppressive nucleotide analog ā« Minimal damage to other organs ā« Facilitated the reduction of genotoxic agents without increasing the risk of engraftment failure
- 39. Management: HSCT ā¢ Matched sibling transplants: ā« Disease free survival -64-89% ā« Essential to test all potential sibling donors for FA ļ If any abnormality is found sugg. Underlying marrow dysfunction testing should be conducted on skin fibroblasts to rule out somatic mosaicism ā¢ Unrelated donor transplants ā« Discouraging results prior to the advent of Fludarabine (<30% overall survival)
- 40. Management: HSCT ā¢ HSCT does NOT correct the non-haematological manifestations of FA ā¢ Solid tumours: ā« SCC ā« risk continues to rise after transplant (4.4 higher age-specific hazard) ā« Arise at an earlier age
- 41. Management: Androgens ā¢ Can improve cytopenias in all three lineages ā¢ Good holding treatment. ā¢ Effect most profound for erythroid lineage ā¢ Subset of patients does not respond at all ā¢ Most patients may respond initially but then become refractory
- 42. Management: Androgens ā¢ Dose should be tapered to the minimum that sustains the blood counts ā¢ May exacerbate liver tumours ā« Regular monitoring of LFT ā« Screening US
- 43. Management: General ā¢ Transfusion support ā¢ Timely institution of appropriate iron chelation ā¢ Treat bleeding ā« Antifibrinolytics ā« Platelets ā¢ Annual bone marrow aspirates and cytogenetic analysis ā¢ Annual surveillance for major solid tumours
- 44. Morbidity/Mortality ā¢ More than 80% of patients reach an age of 18 years ā¢ Major causes of death in FA 1. Bone marrow failure 2. Leukaemia 3. Solid tumours ā¢ Median survival free of any malignancy or tumours 29 years
- 45. Morbidity/Mortality Bone marrow failure ā¢ Usually presents in childhood ā« Petechiae, bruising, haemorrhages ā« Pallor, fatigue ā« infections ā¢ More than 90%develop pancytopenia
- 46. Morbidity/Mortality Leukaemia ā¢ 10% of patients ā¢ Most commonly AML ā¢ risk 600 X >general population Myelodysplastic syndromes ā¢ 6% of patients ā¢ Teens and young adults ā¢ May not have had a phase of aplastic anaemia ā¢ Risk 5000 X >general population
- 47. Morbidity/Mortality Solid tumours ā¢ 10% of patients ā¢ Most common: ā« HNSCC 500X >general population ā« Liver tumours ā« Vaginal squamous cell carcinoma 3000X>general population ā« Brain tumours
- 48. Take home message ā¢ Classical phenotypes originally described for IBFS are the severe end of a highly variable spectrum ā¢ Early recognition allows appropriate medical management and surveilance